MannKind Corporation (NASDAQ:MNKD) Releases Update On Afrezza® Prescribing Information

MannKind Corporation (NASDAQ:MNKD) reported that the U.S. Food & Drug Administration has approved a revision to the Afrezza prescribing information to constitute new clinical data that was showcased at the 76th Scientific Sessions of American Diabetes Association in June 2016. Afrezza inhalation powder is permitted by the FDA to enhance glycemic control in adults with […]

MannKind Corporation (NASDAQ:MNKD) And One Drop To Strike A Collaboration To Help Diabetes Patients

MannKind Corporation (NASDAQ:MNKD) made an announcement about its collaboration with One drop revealing that they were going to engage in a randomized controlled trial. This will be in a bid to investigate the use of Afrezza inhaled insulin. One Drop’s integrated digital diabetes care platform will also be scrutinized further in an effort to identify the […]

Patrick Mccauley To Serve As The New Chief Commercial Officer For MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) is today excited to announce that Patrick McCauley is joining its team of top executive officers. He will serve in the capacity of the company’s Chief Commercial Officer. This will see him lead the provider’s commercials operations. He starts working with immediately, something that will see the company tap from his expertise […]

MannKind Corporation (NASDAQ:MNKD) Draws Remaining Funds under Mann Group Loan Arrangement

MannKind Corporation (NASDAQ:MNKD) has announced serving Mann Group LLC with a funding request notification in regards to the terms of the Mann Group Loan Arrangement to draw the outstanding $30.1 million of the agreement. After receiving the funding, MannKind will use the $10.6 million proceeds for capital and pay off its interest accrued under the […]

MannKind Corporation (NASDAQ:MNKD) Engages Locust Walk To Spark Progress In Mannkind’s Non-Insulin Technosphere-Based Pipeline Candidates

MannKind Corporation (NASDAQ:MNKD), which happens to be a top end company that focuses on discovery, development and commercialization of therapeutic products has made the much awaited announcement. The provider’s board of directors has reached the decision to explore the financial and strategic alternatives for MannKind’s elaborate Technosphere-based pipeline candidates. This Technosphere platform is associated with […]

BIOMM SA And Mannkind Corporation (NASDAQ:MNKD) Collaborate In A Distribution Deal For Afrezza In Brazil

MannKind Corporation (NASDAQ:MNKD) and BIOMM SA today went ahead to make the much awaited announcement. They just made their entry into an agreement that will see them commercialize Afrezza® (insulin human) Inhalation Powder in Brazil. The supply and distribution agreement provides that Biomm will be entrusted with preparing as well as filing the necessary applications […]

Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal

Boston, MA 08/11/2014 (wallstreetpr) – French drug company Sanofi SA (ADR) (NYSE:SNY) and MannKind Corporation (NASDAQ:MNKD) have entered a global collaboration that involves developing and marketing of the inhaled insulin therapy, Afrezza, targeting adults with types 1 and 2 of diabetes. Afrezza is billed as rapid-acting inhaled insulin, a new solution for diabetes patients that […]

Mannkind Corporation (NASDAQ:MNKD): Investors Can Circle April 1 On Their Calendar

Boston, MA 01/13/2013 (wallstreetpr) – That Mannkind Corporation (NASDAQ:MNKD) is becoming a pendulum is causing anxiety somewhere. There isn’t so much that one can say about this stock now except about what investors can expect in the few coming months. Of late the stock soars and pulls back without warning and there is nothing strange […]

MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time

Boston, MA 10/14/2013 (wallstreetpr) –  For the sake of humanity, MannKind Corporation (NASDAQ:MNKD) which so far has no drug on the market hopes its candidate Afrezza will this time get the approval of the Food and Drug Administration (FDA).  The company on Monday announced resubmitting of new drug application to FDA for the drug candidate which […]